.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Citi
Daiichi Sankyo
Deloitte
AstraZeneca
Cantor Fitzgerald
Chubb
Teva
Accenture
Covington

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,521,260

« Back to Dashboard

Summary for Patent: 6,521,260

Title: Carrier particles for use in dry powder inhalers
Abstract:A powder for use in a dry powder inhaler includes active particles and carrier particles for carrying the active particles. The powder further includes additive material (4) on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the inhaler. The powder is such that the active particles are not liable to be released from the carrier particles before actuation of the inhaler. The inclusion of additive material (4) in the powder has been found to give an increased respirable fraction of the active material.
Inventor(s): Staniforth; John Nicholas (Bath, GB)
Assignee: Vectura Limited (Londen, GB)
Application Number:09/680,863
Patent Claim Types:
see list of patent claims
Composition; Delivery; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 6,521,260

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9501841Jan 31, 1995
United Kingdom9521937Oct 26, 1995

International Patent Family for Patent: 6,521,260

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovakia103697► Subscribe
Slovenia1666023► Subscribe
Slovenia1232745► Subscribe
Portugal1666023► Subscribe
Portugal1232745► Subscribe
Portugal806938► Subscribe
Poland186757► Subscribe
Poland321572► Subscribe
New Zealand300654► Subscribe
Norway973502► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Deloitte
Baxter
Johnson and Johnson
Colorcon
Harvard Business School
AstraZeneca
Dow
Fish and Richardson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot